You are here


Human Cell Line for Studies on Signaling and Endocrine Cancer

The National Institute of Child and Human Development seeks interested parties to further co-developa cell line with mutations in PRKAR1A, associated with tumor formation, for use a diagnostic or research tool.
NIH Reference Number
Product Type
  • cAMP signaling
  • RIalpha
  • PKA
Collaboration Opportunity
This invention is available for licensing.
Description of Technology

The first known immortalized cell line with a naturally-occurring inactivating mutation in PRKAR1A, the regulatory subunit type 1A (R1alpha) of protein kinase A (PKA), which is associated with tumor formation.

PKA isozyme balance is critical for the control of cAMP signaling and related cell cycle and proliferation changes. Aberrant cAMP signaling has been linked to adrenocortical and other, mostly endocrine, tumors. Inactivating mutations in the PRKAR1A gene are a known cause of Carney Complex - an autosomal dominant multiple neoplasia syndrome associated with skin, heart, and other myxomas and a variety of endocrine tumors.

Potential Commercial Applications
  • Studies on multiple tumor formation associated with Carney Complex.
  • Characterization of cAMP-mediated mechanisms of endocrine tumor formation.
  • Studies of a large variety of cAMP-mediated processes in normal physiology and disease.
Competitive Advantages
  • First known immortalized cell line with a naturally-occurring inactivating mutation in the  PRKAR1A gene.
Development Stage

Nesterova M, et al. [PMID 18056771]

Patent Status
  • U.S. Patent Filed: U.S. Patent Application Number
Therapeutic Area
Thursday, July 19, 2018